Promising Parkinson’s Drug HL192 Completes Successful First Human Trial

A new experimental drug, HL192, has successfully completed its first human trial, showing promising results for people with Parkinson’s disease. The trial, conducted on 76 healthy volunteers, was designed to assess the safety and tolerability of HL192. The drug met its primary goal, confirming that it is safe for human use. Participants who received HL192 experienced side effects similar to those who received a placebo, meaning the drug did not cause any serious adverse reactions. The doses used in the study were well below the levels that could potentially cause harm, ensuring a favorable safety profile. HL192 is being developed by HanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals, and it works by targeting a key protein called Nurr1. This protein plays a crucial role in the development and maintenance of the brain cells that produce dopamine, which are damaged in Parkinson’s disease. By activating Nurr1, HL192 could help protect and repair these dopamine-producing neurons, offering hope for new treatments for Parkinson’s. Before this trial, HL192 showed positive results in animal studies, where it helped improve motor function and reduced damage to brain cells. The successful completion of this phase 1 trial, supported by a grant from The Michael J. Fox Foundation, is an important step in the development of HL192. The next phase will involve testing the drug in people with Parkinson’s to further evaluate its safety and effectiveness. The Michael J. Fox Foundation, which has been a key partner in supporting this research, remains committed to finding better treatments for the 6 million people worldwide living with Parkinson’s disease. The results of this trial bring renewed hope for those affected by this challenging condition, as researchers continue to explore potential therapies that could slow or even stop the progression of Parkinson’s.